Transforming the Landscape of Cancer Immunotherapy
OmRx Oncology is a pioneering biopharmaceutical company focused on expanding access to life-saving cancer treatments. Our work begins with OX-4224, a small molecule checkpoint inhibitor designed to overcome barriers in regions where traditional antibody-based immunotherapies are out of reach.
Expanding access to life-saving cancer therapies.
Innovating for Global Impact
OX-4224, our small molecule oral immune checkpoint inhibitor targeting the PD-1/PD-L1 pathway, is being evaluated for non-small cell lung cancer (NSCLC). By licensing this Phase 2-ready asset from Gilead Sciences and continuing its development, we are bringing a more affordable and accessible option to regions that need it most.
Making Cancer Immunotherapy Accessible Worldwide
Despite the critical role of immune checkpoint inhibitors in cancer treatment, access remains severely limited outside major markets due to high costs and logistical barriers. OX-4224, as an oral small molecule checkpoint inhibitor, offers a transformative solution with significant advantages over traditional antibody therapies:
- Lower Cost of Therapy
- No Infusion Center Requirement
- Simpler Supply Chain Logistics
Advancing Safer, All-Oral Combination Cancer Treatments
Combining a checkpoint inhibitor with an oral targeted therapy can significantly boost treatment efficacy, but it also increases safety risks that are more difficult to mitigate due to the long clearance times of antibody-based inhibitors. In contrast, oral small molecule checkpoint inhibitors offer greater flexibility and safety in combination regimens, ensuring continuous treatment and better patient outcomes.
- Faster Clearance Rates: Enables timely dose adjustments.
- Reduced Treatment Interruptions: One therapy can continue while the other is paused.
- Improved Safety Profile: Minimizes the risk of immune-related side effects.
Our Trusted Partners
Our team of world-class experts in cancer research, clinical development, and corporate strategy is supported by trusted partners who help drive our mission forward.
